EN
Entera Bio Ltd.
ENTX · NASDAQ
$3.00 +1.69% (+$0.05)
1M -1.32%
Market Cap $147.9M
P/E Ratio -
Div. Yield -
ROE 147.19%
Bulios Fair Price
$2.66
11.3% downside
Current Price
$3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ENTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 20.35x
EV/EBITDA N/A
P/S N/A
Growth
10 /100
Declining Book val. growth 3.68%
Rev. growth 32.07%
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 147.19%
ROA 87.44%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 8.98x
Int. coverage -5.20x
Debt/Equity 0.06x
Stability
58 /100
Moderate EPS volatility 15.71%
Profitable years 0
Beta 1.40x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ENTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Miranda J. Toledano
Employees
21
Headquarters
Jerusalem
Upcoming events
13 NOV
Earnings
Upcoming earnings report